X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs GSK PHARMA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA GSK PHARMA GLENMARK PHARMA/
GSK PHARMA
 
P/E (TTM) x 13.3 48.9 27.3% View Chart
P/BV x 2.4 9.7 24.6% View Chart
Dividend Yield % 0.4 1.6 27.0%  

Financials

 GLENMARK PHARMA   GSK PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
GSK PHARMA
Mar-19
GLENMARK PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs9303,595 25.9%   
Low Rs5171,253 41.3%   
Sales per share (Unadj.) Rs322.6184.7 174.7%  
Earnings per share (Unadj.) Rs28.526.3 108.4%  
Cash flow per share (Unadj.) Rs39.229.2 134.4%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.30.8 33.5%  
Book value per share (Unadj.) Rs183.0126.3 144.9%  
Shares outstanding (eoy) m282.17169.40 166.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.213.1 17.1%   
Avg P/E ratio x25.492.2 27.6%  
P/CF ratio (eoy) x18.583.1 22.2%  
Price / Book Value ratio x4.019.2 20.6%  
Dividend payout %7.076.1 9.2%   
Avg Mkt Cap Rs m204,206410,626 49.7%   
No. of employees `00013.75.0 276.5%   
Total wages/salary Rs m18,7185,372 348.4%   
Avg. sales/employee Rs Th6,636.86,306.7 105.2%   
Avg. wages/employee Rs Th1,364.71,083.1 126.0%   
Avg. net profit/employee Rs Th586.1898.0 65.3%   
INCOME DATA
Net Sales Rs m91,03131,281 291.0%  
Other income Rs m9141,023 89.3%   
Total revenues Rs m91,94532,304 284.6%   
Gross profit Rs m16,1546,009 268.8%  
Depreciation Rs m3,019486 621.2%   
Interest Rs m2,8566 47,595.0%   
Profit before tax Rs m11,1936,540 171.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m3,1552,373 132.9%   
Profit after tax Rs m8,0394,454 180.5%  
Gross profit margin %17.719.2 92.4%  
Effective tax rate %28.236.3 77.7%   
Net profit margin %8.814.2 62.0%  
BALANCE SHEET DATA
Current assets Rs m69,88720,061 348.4%   
Current liabilities Rs m32,87914,543 226.1%   
Net working cap to sales %40.717.6 230.5%  
Current ratio x2.11.4 154.1%  
Inventory Days Days8157 143.4%  
Debtors Days Days9314 665.0%  
Net fixed assets Rs m28,89214,343 201.4%   
Share capital Rs m2821,694 16.7%   
"Free" reserves Rs m51,35319,704 260.6%   
Net worth Rs m51,63521,398 241.3%   
Long term debt Rs m41,4182 2,070,890.0%   
Total assets Rs m125,95439,113 322.0%  
Interest coverage x4.91,091.0 0.5%   
Debt to equity ratio x0.80 858,210.6%  
Sales to assets ratio x0.70.8 90.4%   
Return on assets %8.611.4 75.9%  
Return on equity %15.620.8 74.8%  
Return on capital %15.131.9 47.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,317534 6,801.0%   
Fx outflow Rs m9,7207,091 137.1%   
Net fx Rs m26,598-6,557 -405.6%   
CASH FLOW
From Operations Rs m16,4813,994 412.7%  
From Investments Rs m-10,133-1,433 706.9%  
From Financial Activity Rs m-4,685-3,584 130.7%  
Net Cashflow Rs m1,770-1,023 -173.0%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 6.9 10.2 67.6%  
FIIs % 34.4 23.8 144.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 102,036 55.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   AUROBINDO PHARMA  MERCK  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 300 Points Higher; Energy and Metal Stocks Witness Buying(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 25, 2019 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS